Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma

Cancer Science

Volumn 108, Issue 6, 2017, Pages 1119-1127

  Tsutsumi, Satoshi ^a   Saeki, Hiroshi ^a   Nakashima, Yuichiro ^a   Ito, Shuhei ^a   Oki, Eiji ^a   Morita, Masaru ^a   Oda, Yoshinao ^a   Okano, Shinji ^a,b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Epithelial mesenchymal transition; esophageal cancer; immune system; malignant potential; tumor invasion

Indexed keywords

CD8 ANTIGEN; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; CADHERIN; CD274 PROTEIN, HUMAN; ZEB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CELL NUCLEUS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR DIFFERENTIATION; TUMOR INVASION; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTIGENS, CD274; CADHERINS; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85019869156     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13237     Document Type: Article

References (57)

1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013; 19: 5598–606.
2. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184–7.
3. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993–2001. Jpn J Clin Oncol 2008; 38: 464–8.
4. Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229: 114–25.
5. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813–24.
6. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366: 2517–9.
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64.
8. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18: 6580–7.
9. Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947–53.
10. Umemoto Y, Okano S, Matsumoto Y et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015; 50: 65–75.
11. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66: 3381–5.
12. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757–66.
13. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–54.
14. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–65.
15. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442–54.
16. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420–8.
17. Usami Y, Satake S, Nakayama F et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol 2008; 215: 330–9.
18. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910–4.
19. Yang J, Mani SA, Donaher JL et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927–39.
20. Syed V. TGF-beta signaling in cancer. J Cell Biochem 2016; 117: 1279–87.
21. Ito S, Okano S, Morita M et al. Expression of PD-L1 and HLA class I in esophageal squamous cell carcinoma: prognostic factors for patient outcome. Ann Surg Oncol 2016; 23: 508–15.
22. Joseph JV, Conroy S, Tomar T et al. TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis 2014; 5: e1443.
23. Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell 2007; 18: 3533–44.
24. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–7.
25. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–75.
26. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
27. Ishii H, Azuma K, Kawahara A et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 2015; 10: 426–30.
28. Zhang Y, Liu G, Wu S, Jiang F, Xie J, Wang Y. Zinc finger E-box-binding homeobox 1: its clinical significance and functional role in human thyroid cancer. Onco Targets Ther 2016; 9: 1303–10.
29. Galvan JA, Zlobec I, Wartenberg M et al. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br J Cancer 2015; 112: 1944–50.
30. Soini Y, Tuhkanen H, Sironen R et al. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 2011; 11: 73.
31. + T lymphocyte count is independent of tumor TLR9 status in treatment naive triple negative breast cancer and renal cell carcinoma. Oncoimmunology 2015; 4: e1002726.
32. + T cells in urothelial carcinoma. Urology 2015; 85: 703. e1–6.
33. Uchikado Y, Natsugoe S, Okumura H et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 1174–80.
34. Pakala SB, Singh K, Reddy SD et al. TGF-beta1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene 2011; 30: 2230–41.
35. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156–72.
36. + T cells. Oncol Rep 2016; 35: 699–708.
37. Spranger S, Spaapen RM, Zha Y et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5: 200ra116.
38. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–71.
39. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015; 5: 915–9.
40. Liu J, Chen L, Deng H et al. Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient's survival. Int J Clin Exp Pathol 2014; 7: 6943–9.
41. Saeki H, Oda S, Kawaguchi H et al. Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer 2002; 98: 8–13.
42. Saeki H, Kuwano H, Kawaguchi H, Ohno S, Sugimachi K. Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer 2000; 89: 1670–6.
43. Ock CY, Kim S, Keam B et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 2016; 7: 15901–14.
44. Cao Y, Zhang L, Kamimura Y et al. B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res 2011; 71: 1235–43.
45. Alsuliman A, Colak D, Al-Harazi O et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015; 14: 149.
46. Vannier C, Mock K, Brabletz T, Driever W. Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development. J Biol Chem 2013; 288: 18643–59.
47. Sanchez-Tillo E, Lazaro A, Torrent R et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010; 29: 3490–500.
48. Rosenbloom KR, Armstrong J, Barber GP et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015; 43: D670–81.
49. Chen L, Gibbons DL, Goswami S et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5: 5241.
50. Noman MZ, Janji B, Abdou A et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 2017; 6: e1263412.
51. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 2015; 51: 221–8.
52. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003; 100: 5336–41.
53. Liu J, Hamrouni A, Wolowiec D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296–304.
54. Qian Y, Deng J, Geng L et al. TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest 2008; 26: 816–21.
55. Baas M, Besancon A, Goncalves T et al. TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 2016; 5: e08133.
56. Song S, Yuan P, Wu H et al. Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol 2014; 20: 117–23.
57. Ou JN, Wiedeman AE, Stevens AM. TNF-alpha and TGF-beta counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep 2012; 2: 295.